Management of Bronchopneumonia
For community-acquired bronchopneumonia, start empiric antibiotics immediately based on severity: outpatients receive oral amoxicillin (or a macrolide if penicillin-allergic), hospitalized non-severe cases get combination therapy with amoxicillin plus a macrolide, and severe cases requiring ICU admission need IV broad-spectrum β-lactam (cefotaxime, ceftriaxone, or co-amoxiclav) plus a macrolide. 1
Severity Assessment and Site-of-Care Decision
Begin by stratifying severity to determine treatment location. Use the CURB-65 criteria (Confusion, Uremia, Respiratory rate ≥30, Blood pressure <90/60 mmHg, age ≥65 years) or Pneumonia Severity Index 2:
- CURB-65 score 0-1: Outpatient management appropriate
- CURB-65 score ≥2: Hospitalization warranted 2
- ICU admission criteria: Septic shock requiring vasopressors, acute respiratory failure requiring mechanical ventilation, or ≥3 minor severity criteria 2
Supplement objective scores with assessment of ability to take oral medications reliably and availability of outpatient support 2.
Antibiotic Selection by Setting
Community/Outpatient Management
First-line: Amoxicillin at higher doses than historically used 1
Alternative: Macrolide (erythromycin or clarithromycin) for penicillin-allergic patients 1
Critical caveat: If illness is life-threatening or hospital admission will be delayed >2 hours, administer antibiotics immediately in the community before transfer 1
Hospitalized Non-Severe Cases
Preferred regimen: Oral combination therapy with amoxicillin plus a macrolide (erythromycin or clarithromycin) 1
Monotherapy considerations:
- Amoxicillin alone: For previously untreated patients or those admitted for non-clinical reasons (elderly, socially isolated) 1
- Macrolide alone: May be suitable if failed adequate amoxicillin course pre-admission, though combination therapy remains preferred 1
When oral contraindicated: IV ampicillin or benzylpenicillin plus IV erythromycin or clarithromycin 1
Alternative: Fluoroquinolones with enhanced pneumococcal activity (levofloxacin) for penicillin/macrolide intolerance or local Clostridium difficile concerns, though experience is limited 1
Severe Cases (ICU or High-Dependency)
Standard regimen: IV broad-spectrum β-lactam (co-amoxiclav, cefuroxime, cefotaxime, or ceftriaxone) plus macrolide (clarithromycin or erythromycin) 1, 3
Alternative: Fluoroquinolone with enhanced pneumococcal activity (moxifloxacin or levofloxacin 750mg/24h) ± non-antipseudomonal third-generation cephalosporin 3
If Pseudomonas aeruginosa risk (COPD, mechanical ventilation >7 days, prior antibiotics): Antipseudomonal cephalosporin OR acylureidopenicillin/β-lactamase inhibitor OR carbapenem (meropenem preferred) PLUS ciprofloxacin OR macrolide plus aminoglycoside 4, 3
Supportive Care
Oxygen Therapy
- Target PaO₂ >8 kPa and SaO₂ >92% 1
- High-concentration oxygen is safe in uncomplicated pneumonia 1
- COPD patients: Guide oxygen by repeated arterial blood gases to avoid ventilatory failure 1
Monitoring Parameters
Monitor and record at least twice daily (more frequently in severe cases) 1:
- Temperature, respiratory rate, pulse, blood pressure
- Mental status
- Oxygen saturation and FiO₂
Fluid and Nutritional Support
- Assess for volume depletion; provide IV fluids as needed 1
- Nutritional support in prolonged illness 1
Duration of Therapy
For non-severe cases reaching clinical stability: Minimum 3 days, acceptable to stop at <5 days rather than continuing ≥5 days 5, 6
For severe CAP: Continue ≥5 days 6
General principle: Duration should not exceed 8 days in responding patients 3
Important: Prolonging antibiotic treatment does not prevent recurrences 4
Modification Based on Microbiology
- Tailor therapy when culture results available; de-escalation reduces resistance rates 4
- Direct Gram stain can provide immediate guidance when read by experienced observers 4
- Bronchoscopy with quantitative cultures improves survival in suspected cases and frequently prompts antibiotic changes 4
Response Assessment and Follow-Up
Early Assessment
- Reassess at 48 hours or earlier if clinically indicated 1
- Remeasure CRP and repeat chest radiograph if not progressing satisfactorily 1
- Do not repeat chest radiograph before discharge if satisfactory clinical recovery achieved 1
Follow-Up Planning
- Clinical review at 6 weeks with GP or hospital clinic 1
- Chest radiograph at 6 weeks for persistent symptoms/signs or high malignancy risk (smokers, age >50) 1
- Consider bronchoscopy for persisting abnormalities 6 weeks post-treatment 1
Special Considerations
Ventilator-associated pneumonia: Antibiotic choice must account for prior antibiotic exposure; Gram-positive cocci and Haemophilus influenzae associate with no prior antibiotics, while non-fermentative Gram-negatives relate to previous antibiotic use 4
MRSA suspicion: Consider if Glasgow Coma Scale <8, but not expected without prior antibiotic administration; vancomycin for MRSA VAP has very poor outcomes 4
Candida colonization: Antifungal therapy not required even when present 4
Corticosteroids: Recommended only for severe CAP without influenza virus infection; not recommended for non-severe pneumonia 5, 6